Physician profile
Syed Arshad
NPI 1255395125
$3,477.71
in general payments reported to CMS, 2019-2025
39 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $635 · 2021: $559 · 2022: $640 · 2023: $48.52 · 2024: $364 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $409.44 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $408.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $266.87 | 2019-2021 | |
| Lilly USA, LLC | $213.77 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $193.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $188.48 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $171.42 | 2021-2025 | |
| Pfizer INC. | $137.45 | 2021-2022 | |
| Edwards Lifesciences Corporation | $124.81 | 2024-2025 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $117.84 | 2020-2023 | Padcev |
| Medtronic Vascular, INC. | $103.24 | 2019 | |
| Abbott Laboratories | $94.59 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $91.96 | 2024 | |
| Sanofi-Aventis U.S. LLC | $87.33 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.77 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.